SCHEMBL5097997

SCHEMBL5097997

CN(C)c1ccc(N)c(N2CCCCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.59
GAA P10253 7/20 0.59
HTT P42858 4/20 0.59
MAPT P10636 4/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
L3MBTL1 Q9Y468 3/20 0.59
S100B P04271 2/20 0.59
LMNA P02545 2/20 0.59
MAPK1 P28482 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
PKM P14618 1/20 0.59
ALOX15 P16050 1/20 0.59
KEAP1 Q14145 1/20 0.50
KDM4E B2RXH2 5/20 0.44
RECQL P46063 2/20 0.44
PTK2B Q14289 2/20 0.44
POLB P06746 2/20 0.42
THRB P10828 2/20 0.41
TDP2 O95551 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL7519014 0.82 GAA (0.44) ALDH1A1GAAHTTMAPTMEN1
SCHEMBL3534495 0.82 CSF1R (0.52) ALDH1A1GAAHTTMAPTMEN1
SCHEMBL5098003 0.82 GAA (0.50) ALDH1A1GAAHTTMAPTMEN1
SCHEMBL1339840 0.77 ALDH1A1 (0.65) ALDH1A1GAAHTTMAPTMEN1
SCHEMBL5097993 0.76 NPC1 (0.56) ALDH1A1GAAHTTMAPTMEN1
SCHEMBL28147210 0.76 GAA (0.69) ALDH1A1GAAHTTMAPTMEN1
SCHEMBL20621607 0.74 NTSR1 (0.45) ALDH1A1GAAHTTMAPTMEN1
SCHEMBL22854083 0.74 SLC9A1 (0.43) ALDH1A1GAAMAPTLMNAMAPK1
SCHEMBL1339913 0.74 MAPT (0.61) ALDH1A1GAAHTTMAPTMEN1
SCHEMBL3538453 0.74 ALDH1A1 (1.00) ALDH1A1GAAHTTMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP claimed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO claimed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 US claimed
US-7427683-B2 c-fms kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-09-23 US disclosed
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP disclosed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131022-A1 C-fms kinase inhibitors FLT3, FES, FGR ALDH1A1 4568/4885GAA 4542/4885HTT 2073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.